Switch theme
Sign up to access all valuation multiples
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
2014
205
Last FY Revenue n/a
LTM EBITDA -$221M
$499M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cogent Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$221M.
In the most recent fiscal year, Cogent Biosciences achieved revenue of n/a and an EBITDA of -$272M.
Cogent Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cogent Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$221M | XXX | -$272M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$280M | XXX | -$276M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$265M | XXX | -$256M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cogent Biosciences's stock price is $5.
Cogent Biosciences has current market cap of $619M, and EV of $499M.
See Cogent Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $499M | $619M | XXX | XXX | XXX | XXX | $-2.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cogent Biosciences has market cap of $619M and EV of $499M.
Cogent Biosciences's trades at n/a EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Cogent Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cogent Biosciences has a P/E ratio of -2.3x.
See valuation multiples for Cogent Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $619M | XXX | $619M | XXX | XXX | XXX |
| EV (current) | $499M | XXX | $499M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -1.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -3.0x | XXX | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCogent Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Cogent Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cogent Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cogent Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cogent Biosciences acquired XXX companies to date.
Last acquisition by Cogent Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Cogent Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cogent Biosciences founded? | Cogent Biosciences was founded in 2014. |
| Where is Cogent Biosciences headquartered? | Cogent Biosciences is headquartered in United States of America. |
| How many employees does Cogent Biosciences have? | As of today, Cogent Biosciences has 205 employees. |
| Who is the CEO of Cogent Biosciences? | Cogent Biosciences's CEO is Mr. Andrews R. Robbins, M.B.A.. |
| Is Cogent Biosciences publicy listed? | Yes, Cogent Biosciences is a public company listed on NAS. |
| What is the stock symbol of Cogent Biosciences? | Cogent Biosciences trades under COGT ticker. |
| When did Cogent Biosciences go public? | Cogent Biosciences went public in 2018. |
| Who are competitors of Cogent Biosciences? | Similar companies to Cogent Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cogent Biosciences? | Cogent Biosciences's current market cap is $619M |
| Is Cogent Biosciences profitable? | Yes, Cogent Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cogent Biosciences? | Cogent Biosciences's last 12 months EBITDA is -$221M. |
| What is the current EV/EBITDA multiple of Cogent Biosciences? | Current EBITDA multiple of Cogent Biosciences is -2.3x. |
| What is the current FCF of Cogent Biosciences? | Cogent Biosciences's last 12 months FCF is -$164M. |
| What is the current EV/FCF multiple of Cogent Biosciences? | Current FCF multiple of Cogent Biosciences is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
